Alto Neuroscience (ANRO) Cash & Equivalents (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Cash & Equivalents data on file, last reported at $263.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 64.08% year-over-year to $263.8 million; the trailing twelve-month figure through Mar 2026 stood at $263.8 million (up 64.08% YoY), and the FY2025 full-year result was $176.5 million, up 4.93% from the prior year.
• Cash & Equivalents rose to $263.8 million in Q1 2026, from $176.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $263.8 million in Q1 2026 to a low of $82.5 million in Q4 2023.
• A 4-year average of $171.8 million and a median of $172.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 103.76% in 2024 and fell 24.15% in 2025, its largest moves.
• Tracing ANRO's Cash & Equivalents over 4 years: stood at $82.5 million in 2023, then jumped by 103.76% to $168.2 million in 2024, then rose by 4.93% to $176.5 million in 2025, then soared by 49.45% to $263.8 million in 2026.
• Business Quant data shows ANRO's Cash & Equivalents at $263.8 million in Q1 2026, $176.5 million in Q4 2025, and $137.8 million in Q3 2025.